SCHEMBL6406565

SCHEMBL6406565

COc1ccc(CCNc2nnc(-c3ccc(F)c(F)c3Nc3ccc(I)cc3F)o2)cc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.39
CAMK2B Q13554 1/20 0.39
FLT1 P17948 2/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 3/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 2/20 0.38
MAP2K1 Q02750 6/20 0.38
MAP2K2 P36507 4/20 0.38
TP53 P04637 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ATM Q13315 1/20 0.37
LMNA P02545 5/20 0.37
TSHR P16473 3/20 0.37
MAPT P10636 3/20 0.37
MAPK1 P28482 3/20 0.37
HTT P42858 1/20 0.37
KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6207706 0.88 ALDH1A1 (0.38) PIM1CAMK2BFLT1ALDH1A1KDM4E
SCHEMBL6400835 0.87 DUSP3 (0.37) PIM1CAMK2BFLT1ALDH1A1KDM4E
SCHEMBL6404352 0.84 MAP2K1 (0.41) PIM1CAMK2BFLT1MAP2K1MAP2K2
SCHEMBL6208038 0.84 PIM1 (0.45) PIM1CAMK2BMAP2K1MAP2K2MAPK1
SCHEMBL6400824 0.84 MAP2K1 (0.38) PIM1CAMK2BFLT1ALDH1A1KDM4E
SCHEMBL6187892 0.83 MAP2K1 (0.45) PIM1CAMK2BMAP2K1MAP2K2MAPK1
SCHEMBL6400821 0.83 TP53 (0.40) PIM1CAMK2BFLT1MAP2K1MAP2K2
SCHEMBL21067809 0.83 MAP2K1 (0.46) PIM1CAMK2BMAP2K1MAP2K2MAPK1
SCHEMBL6406299 0.83 PIM1 (0.44) PIM1CAMK2BALDH1A1KDM4EHPGD
SCHEMBL6398520 0.82 PIM1 (0.46) PIM1CAMK2BMAP2K1MAP2K2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 PIM1 74/4885CAMK2B 1041/4885FLT1 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.